What drugs does Hikma make?
Hikma Pharmaceuticals manufactures and markets a comprehensive portfolio of branded, generic, and injectable pharmaceutical products across global healthcare markets. Its extensive manufacturing output features vital intravenous hospital injectables, sterile products, anti-infectives, and specialized central nervous system medications. Additionally, Hikma produces a wide range of oral chronic-care medications covering cardiovascular conditions, diabetes, pain management, and respiratory therapies, supplying essential medicines directly to hospitals, clinics, and retail pharmacies worldwide.
Related FAQs
Hikma Pharmaceuticals (LSE: HIK) maintains a consistent dividend policy as part of its commitment to delivering value to shareholders. As of the latest financial reporting period in 2026, the company’s dividend yield is approximately 1.70% to 1.
Hikma Pharmaceuticals PLC, a major multinational pharmaceutical enterprise specializing in the development, manufacturing, and marketing of a broad range of branded, generic, and injectable medicines, has its global corporate headquarters located in ...
Financial market analysts evaluating Hikma Pharmaceuticals generally assign a favorable buy or hold recommendation, driven by its robust portfolio of injectable drugs, branded pharmaceuticals, and generic medications.
Hikma Pharmaceuticals manufactures its extensive portfolio of injectable, branded, and generic pharmaceutical products across a specialized network of advanced production facilities located globally.
Employee remuneration at Oshkosh Corporation manufacturing facilities, defense vehicle plants, and specialty equipment centers varies based on technical roles and industrial labor benchmarks.
Large, established pharmaceutical and biotechnology companies are widely recognized by investors for offering stable and attractive dividend yields.
Pharmaceutical sales representatives and regional account managers at Hikma Pharmaceuticals earn average annual base salaries ranging from USD 70,000 to USD 105,000.
Equity research analysts tracking Hikma Pharmaceuticals generally evaluate the multinational pharmaceutical stock with a favorable buy or hold consensus, driven by its robust portfolio of injectable medicines, branded generics, and respiratory produc...
Hikma Pharmaceuticals is frequently viewed by institutional portfolio managers as a solid long-term investment within the healthcare sector due to its diversified product mix, defensive growth characteristics, and resilient global market demand for e...
Hikma Pharmaceuticals is not an American company, having been founded in Jordan and maintaining its primary operational headquarters in London, United Kingdom.
Hikma Pharmaceuticals maintains its primary United States corporate offices, commercial operations, and manufacturing divisions anchored in Berkeley Heights, New Jersey.
The global pharmaceutical industry is dominated by massive multinational corporations that generate tens of billions of dollars in annual prescription drug sales, driven by blockbuster oncology treatments, immunology blockbusters, and vaccines.
Hills Bank operates as an independent community bank headquartered in Iowa, and its operational footprint differs fundamentally from massive national mega-banks.
Hikma Pharmaceuticals is a completely authentic, highly respected multinational pharmaceutical corporation publicly listed on the London Stock Exchange and included in the FTSE 100 index.
Hikma Pharmaceuticals specializes in developing, manufacturing, and marketing a broad spectrum of branded and generic injectable, non-injectable, and inhalation pharmaceutical products.
Hikma Pharmaceuticals stands as a highly respected, multinational pharmaceutical enterprise recognized for manufacturing high-quality generic, injectable, and branded medications distributed globally.